Compare compound mechanisms, evidence quality, related research topics, receptor considerations, and live COA-verified prices. Add 1–5 compounds.
Research signals
Redundancy, true conflicts, and dangerous additive effects
Review advised
No documented conflicts — some notes to review
Receptor activity map
| Receptor | Triple Agon… | GHK-Cu | NAD+ | Tesamorelin |
|---|---|---|---|---|
| GLP-1R (Glucagon-like peptide-1 receptor) | ||||
| GIPR (Glucose-dependent insulinotropic polypeptide receptor) | ||||
| GcgR (Glucagon receptor) | ||||
| Y2R (Neuropeptide Y2 receptor) | ||||
| GHRH receptor (GHRHR) | ||||
| Copper-dependent enzyme pathways (lysyl oxidase, antioxidant defense) | ||||
| TGF-β signaling pathway | ||||
| NAD+-dependent mitochondrial biogenesis pathway |
+1 more receptor
A structured review of the evidence for this stack
Sign in to build a structured evidence review for GHK-Cu + NAD+ + Triple Agonist + Tesamorelin — mechanisms, evidence, endpoints, and limitations grounded in documented research.
Aggregate research activity for this selection
No researchers have logged this exact combination yet — yours could be the first.
Researchers are also adding
Best price for each compound today
Same “From” price shown on each compound's page (after discounts). Panels = COA assays tested. Tap “Compare all vendors” for the full breakdown.
For research and informational use only. VialTalk does not provide medical advice or dosing guidance. Community data reflects self-reported public research journals.
